Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

详细信息    查看全文

• 作者：Reina Watanabe ; Naoto Tomita ; Kumiko Kishimoto ; Satoshi Koyama ; Eriko Ogusa ; Yoshimi Ishii ; Kazuho Miyashita ; Shiro Matsuura ; Shin Fujisawa ; Yukako Hattori ; Hirotaka Takasaki ; Atsuko Fujita ; Rika Ohshima ; Hideyuki Kuwabara ; Chizuko Hashimoto ; Katsumichi Fujimaki ; Rika Sakai ; Yoshiaki Ishigatsubo
• 关键词：Monocyte ; Follicular lymphoma ; Prognosis
• 刊名：Leukemia Research
• 出版年：2013
• 出版时间：October, 2013
• 年：2013
• 卷：37
• 期：10
• 页码：1208-1212
• 全文大小：611 K

文摘

Elevated absolute monocyte counts (AMCs) have been reported to indicate poor prognosis for patients with lymphoproliferative disease, including those with follicular lymphoma (FL) receiving various treatments. We evaluated the prognostic impact of AMC in 150 consecutive FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Progression-free survival (PFS) did not differ significantly according to the AMC level. Univariate and multivariate analyses did not indicate a prognostic significance of AMC for PFS. Thus, the AMC is not a prognostic factor for FL patients treated with R-CHOP. However, immunochemotherapy might influence the prognostic impact of AMC.